MYL-1402O: A Bevacizumab Biosimilar.

ABSTRACT: MYL-1402O (Abevmy^®, Lextemy^®) is a biosimilar of the reference anti-vascular endothelial growth factor antibody bevacizumab. Abevmy^® is approved for use in all indications for which reference bevacizumab is approved, including the treatment of non-small cell lung cancer (NSCLC) and other solid cancers. Lextemy^® is approved for all indications as reference bevacizumab, except in recurrent ovarian cancer. MYL-1402O has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab, and the pharmacokinetic similarity of the agents has been shown in healthy male subjects. MYL-1402O demonstrated clinical efficacy equivalent to that of reference bevacizumab in patients with non-squamous NSCLC. The tolerability, safety and immu

SUBMITTER: Lee A 

PROVIDER: S-EPMC9015968 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature